Contemporary external validation of the Leibovich model for prediction of progression after radical surgery for clear cell renal cell carcinoma

Beisland, Christian; Guðbrandsdottir, Gigja; Reisæter, Lars Anders Rokne; Bostad, Leif; Wentzel‐Larsen, Tore; Hjelle, Karin M.

doi:10.3109/21681805.2014.980844

Cited by 20 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recurrence patterns in ccRCC are complex, and owing to a lack of comparative studies, optimal strategies for FU have not been established [7,13,14]. The current RECUR study showed 5-yr estimated RRs for ccRCC in line with earlier reports [2,15,16]. We found PC recurrences in almost half (45.8%) of the ccRCC patients with recurrence, in keeping with previous publications [9,[17][18][19].…”

Section: Discussionsupporting

confidence: 89%

Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis

Dabestani

Beisland

Stewart

et al. 2019

European Urology Focus

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis

Dabestani

Beisland

Stewart

et al. 2019

European Urology Focus

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this model, the metastatic risk of postoperative RCC patients, rather than their survival, was the primary predictive goal. Internal validation yielded a discrimination of 0.819, while external validations, performed in different clinical centers, demonstrated a c‐index between 0.740 and 0.864; these values seem acceptable. Tan et al applied the Leibovich score to predict OS and DFS in Singaporean RCC patients and found that the prediction effect was poor (c‐index for OS and DFS: 0.670 and 0.700, respectively) .…”

Section: Discussionmentioning

confidence: 89%

Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma

et al. 2019

View full text Add to dashboard Cite

Objectives:To investigate the survival characteristics of postoperative nonmetastatic renal cell carcinoma (RCC) patients, and the predictive value of a prognostic model. Materials and Methods:We retrospectively evaluated data from 1202 postoperative nonmetastatic RCC patients who were treated between 1999 and 2012 at West China Hospital, Sichuan University (Chengdu, China). In addition, we also evaluated data relating to 53 205 cases acquired from the Surveillance, Epidemiology, and End Results (SEER) program. Survival analysis was performed on the cases, and subgroups, using the Kaplan-Meier and Cox regression methods. The concordance index of the Stage Size Grade Necrosis (SSIGN), Leibovich, and the UCLA integrated staging system, scores was determined to evaluate the accuracy of these outcome prediction models. Results:The 5-year overall survival rate for RCC cases in West China Hospital was 87.6%; this was higher than that observed for SEER cases. Survival analysis identified several factors that exerted significant influence over prognosis, including the time of surgery, Eastern Cooperative Oncology Group performance status, tumor stage, size, nuclear differentiation, pathological subtypes, along with necrotic and sarcomatoid differentiation. Moreover tumor stage, size, and nuclear grade were all identified as independent predictors for both our cases and those from the SEER program. Patient groups with advanced RCC, and poorly differentiated RCC subgroups, were both determined to have a poor prognosis. The SSIGN model yielded the best predictive value as a prognostic model, followed by the Leibovich, and UCLA integrated staging system; this was the case for our patients, and for sub-groups with a poor prognosis. Conclusion: The prognosis of RCC was mostly influenced by tumor stage, size, and nuclear differentiation. SSIGN may represent the most suitable prognostic model for the Chinese population. |SHAO et Al.

show abstract

“…One score, the SSIGN, was developed at the Mayo Clinic (also known as the Leibovich score) and classified patients with ccRCC into low‐risk, intermediate‐risk, or high‐risk categories, according to s tage, tumor si ze, nuclear g rade, and the presence of tumor n ecrosis . This score has been externally validated in different institutions, and the prognostic accuracy (Harrel concordance) index ranged between 0.78 and 0.86 …”

Section: The Role Of Systemic Therapy For Localized Diseasementioning

confidence: 99%

“…17,18 This score has been externally validated in different institutions, and the prognostic accuracy (Harrel concordance) 19 index ranged between 0.78 and 0.86. 20,21 The University of California Los Angeles Integrated Staging System (UISS) defines low-risk, intermediate-risk, and high-risk prognostic groups based on stage, Fuhrman nuclear grade, and Eastern Cooperative Oncology Group performance status. The UISS score has been developed for the classification of patients with both localized and advanced disease, 22,23 with an accuracy index ranging between 0.79 and 0.86.…”

Section: The Role Of Systemic Therapy For Localized Diseasementioning

confidence: 99%

Treatment of renal cell carcinoma: Current status and future directions

Barata

Rini

2017

CA A Cancer J Clinicians

614

528

View full text Add to dashboard Cite

Answer questions and earn CME/CNE Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned from a nonspecific immune approach (in the cytokine era), to targeted therapy against vascular endothelial growth factor (VEGF), and now to novel immunotherapy agents. Multiple agents-including molecules against vascular endothelial growth factor, platelet-derived growth factor, and related receptors; inhibitors of other targets, such as the mammalian target of rapamycin and the MET and AXL tyrosine-protein kinase receptors; and an immune-checkpoint inhibitor-have been approved based on significant activity in patients with advanced RCC. Despite these advances, important questions remain regarding biomarkers of efficacy, patient selection, and the optimal combination and sequencing of agents. The purpose of this review is to summarize present management and future directions in the treatment of metastatic RCC. CA Cancer J Clin 2017;67:507-524. © 2017 American Cancer Society.

show abstract

Contemporary external validation of the Leibovich model for prediction of progression after radical surgery for clear cell renal cell carcinoma

Cited by 20 publications

References 21 publications

Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis

Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis

Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma

Treatment of renal cell carcinoma: Current status and future directions

Contact Info

Product

Resources

About